How to use nesiritide in treating decompensated heart failure.
Nesiritide (Natrecor), a synthetic formulation of B-type natriuretic peptide (BNP), is the first new parenteral agent to be approved for treating heart failure in more than a decade. In patients hospitalized with decompensated congestive heart failure, nesiritide promptly reduces pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and systemic vascular resistance, resulting in clinical improvement.
Mills
Roger M
RM
Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA. millsr@ccf.org
Hobbs
Robert E
RE
D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D020097:Natriuretic Peptide, Brain
D002316:Cardiotonic Agents; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor